With dermatologic side effects being fairly prevalent following vaccination against COVID‐
19, and the multitude of studies aiming to report and analyze these adverse events, the need …

Janus kinases (JAKs) are a group of intracytoplasmic tyrosine kinase proteins that bind to
the cytoplasmic part of the transmembrane cytokine receptors and regulate signaling. The …

While mucocutaneous manifestations of COVID-19 have been frequently reported and
added to our knowledge every day during the pandemic, another issue is the COVID-related …

Objectives Earlier diagnosis and the best management of virus‐related, drug‐related or
mixed severe potentially life‐threatening mucocutaneous reactions of COVID‐19 patients …

Cases of filler reactions after COVID‐19 vaccination have been reported. Here, we present
the first case of delayed‐type reaction (DTR) to non‐hyaluronic acid Polycaprolactone …

This narrative review article was conducted to lay out a summarized but exhaustive review of
current literature over mucocutaneous manifestations in 4 dimensions of SARS‐CoV‐2 …

Immune thrombocytopenia (ITP) treatment has evolved recently. However, none of the
treatments have only benefits without drawbacks. This study aimed to compare the clinical …

The ongoing COVID‐19 pandemic has raised concerns regarding the outcome of this
infection in patients with autoimmune bullous dermatoses (AIBDs) due to effect of drugs …

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder caused by antigen-
specific T cells and antiplatelet autoantibodies that inhibit platelet production in the bone …

Background Rituximab (RTX) is considered the first-line treatment for pemphigus vulgaris
(PV), which is a B-cell-mediated acquired autoimmune disease. However, no consensus on …